In a release on
-During the quarter the company executed two master services agreements with two global Pharma companies to develop proof-of- concept immunogenicity assays in its Diagnostics Tools and Services business. These global Pharma projects allow SQI to leverage its existing IVD technology and existing platforms to address the needs of pharmaceutical companies in the drug testing market. The names of the global pharmaceutical companies have been omitted owing to confidentiality agreements with both of the entities and
-Global Pharma 1: During and subsequent to quarter-end SQI completed commercialization milestones in the development of a proof- of-concept anti-drug-antibody ("
-Global Pharma 2 - project 1: SQI completed all development milestones for the previously disclosed proof-of-concept assay in collaboration with Global Pharma 2. This Custom PLEX ADA assay will measure the immune responses in clinical trials to one of the customer's in-development biologic drugs. This 21 biomarker assay takes full advantage of SQI's multiplexing capabilities and has met or exceeded all project goals. The target drug used in this proof- of-concept project is in Global Pharma 2's clinical trials and if adopted commercially, SQI's Custom PLEX ADA product would be used for testing during human clinical trials. The Company expects to deliver Custom PLEX ADA kits in September that will be evaluated for commercial feasibility by Global Pharma 2.
-Global Pharma 2 - project 2: SQI also made significant progress on the commercial demonstration of an 8-plex cytokine assay for Global Pharma 2.
In a release on